The natriuretic peptides in hypertension

Area of Science:

• Cardiovascular Physiology
• Endocrinology
• Nephrology

Background:

• The natriuretic peptide family comprises three key members: atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP).
• ANP and BNP share similar physiological effects, including natriuresis, vasodilation, and renin-angiotensin-aldosterone system suppression.
• CNP primarily impacts the vasculature, promoting vasodilation and inhibiting smooth muscle cell proliferation.

Purpose of the Study:

• To review the current understanding of natriuretic peptide (NP) function in physiological and pathophysiological states.
• To explore the potential therapeutic applications of NPs in managing hypertensive disease.
• To discuss the implications of recent research on NP gene expression, biosynthesis, secretion, and receptor interactions.

Main Methods:

• Literature review of studies on natriuretic peptide family members.
• Analysis of research on NP regulation, including gene expression and receptor binding.
• Examination of the role of NPs in cardiovascular, renal, and endocrine systems.

Main Results:

• Natriuretic peptides play significant roles in regulating blood pressure, fluid balance, and vascular tone.
• Understanding NP pathways has advanced knowledge of their actions in normal and disease states, particularly hypertension.
• Research highlights the potential of targeting NP pathways for therapeutic interventions.

Conclusions:

• Natriuretic peptides are crucial regulators of cardiovascular and renal function.
• Further investigation into nonpeptide neutral endopeptidase inhibitors and NP receptor antagonists shows promise for hypertension treatment.
• Targeting natriuretic peptide systems offers a potential therapeutic avenue for managing hypertensive disease.